The size of the Global Antibodies Market was valued at USD 130.9 Billion in 2019 and estimated to reach USD 223.7 Billion by the end of 2024 with a growing potential of 11.31% during the forecast period 2019-2024.
Antibodies are proteins that are produced in response to specific antigens by plasma cells. They are also called immunoglobulin. These antibodies are used as diagnostics as well as Therapeutic purposes for several indications of diseases, including but not limited to, rheumatoid arthritis, non-Hodgkin lymphoma, psoriasis, Crohn’s disease, macular degeneration, hypercholesterolemia, and asthma. Owing to a number of product launches, the antibodies market is projected to witness steady growth. Effective harmonization of product development, approval and registration guidelines in some of the major markets, such as the United States and European Union can speed up the research and development of antibody-related products.
Major factors that are primarily driving the Global antibodies market are continuous development of innovative products, increased adoption rate to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses owing to population shift and increasing longevity, swift approval by regulatory authorities for breakthrough therapies, and adoption of diagnostic antibodies. Companies are adopting various strategies, like the expansion of product indications to sustain the dynamically growing market.
The high cost of treatment and side effects associated with antibodies treatment can hamper the growth of the global antibodies market.
REPORT COVERAGE
|
Report Metric |
Details |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 – 2024 |
|
Segments Analysed |
By Product Type, Indication, End User, Application and Region |
|
Regions Analysed |
North America (United States and Canada), Europe (UK, Spain, Germany, Italy, France and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, New Zealand, Rest of APAC), Latin America (Brazil, Argentina, Mexico and Rest of Latin America), Middle East and Africa |
|
Companies Analysed |
Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly and company, A.G. Scientific, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, AbbVie Inc |
This research report on the Global Antibodies Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
Antibodies Market - By Product Type:
On the Basis of Product Type, Monoclonal antibodies segment accounts for the highest market share in the market.
Antibodies Market - By Indication:
Antibodies Market - By End User:
On the Basis of End User, the Cancer indication type segment is predicted to account highest market share over the forecast period due to broad range applications of monoclonal antibodies for the treatment of various cancers.
Antibodies Market – By Application:
On the Basis of Application, Hospitals are predicted to account for the highest share in the global antibodies market during the forecast period.
Antibodies Market – By Region:
Promising Companies leading the Global Antibodies Market profiled in the report are:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Monoclonal Antibodies
5.1.1.1 Murine
5.1.1.2 Chimeric
5.1.1.3 Humanized
5.1.1.4 Human
5.1.2 Polyclonal Antibodies
5.1.2.1 Type I
5.1.2.2 Type II
5.1.2.3 Type III
5.1.2.4 Type IV
5.1.2.5 Type V
5.1.2.6 Type VI
5.1.2.7 Type VII
5.1.2.8 Type VIII
5.1.3 Antibody-Drug Complexes
5.1.3.1 Immunogen Technology
5.1.3.2 Seattle Genetics Technology
5.1.3.3 Immunomedics Technology
5.2 By Indication
5.2.1 Cancer
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Abbott Diagnostics (U.S.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 A.G. Scientific, Inc. (U.S.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 AbbVie Inc. (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
